~~<i id='E4DAE52E56'><strike id='E4DAE52E56'><tt id='E4DAE52E56'><pre id='E4DAE52E56'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

comprehensive

author：comprehensive 2025-09-06 03:28:00 - browse：85

JOHNSON & JOHNSON HEADQUARTERS — Daniel Hulshizer/AP

Eight months into his tenure, Johnson & Johnson’s R&D chief is putting a big emphasis on medicines for cancer, treatment-resistant depression, and autoimmune disease.

To sharpen that focus, R&D chief John Reed told STAT that the company is de-emphasizing two areas that have been mainstays for the drug and medical device giant: infectious disease and vaccines, as well as medicines targeting kidney disease and rare eye conditions.

The disclosures were made in an interview ahead of an investor meeting Reed is leading Tuesday aimed at generating excitement about the company’s research and development efforts.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Immunocompromised patients offer clues on chronic Covid

knowledge

focus

hotspot

explore

focus

AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo

WSS

Dog Aging Project founders on what lies ahead after losing funding

Printout prescription drug information shouldn’t go digital

Maisha Meds is a PBM, but don't call it that

First Opinion on colorectal cancer screening: letter and response

Scientific mystery highlights the blind spots in genomics databases

Study: Black kids more likely to die after surgery than white kids

knowledge

comprehensive

knowledge

The high cost of giving birth even with insurance

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Alkermes shareholders re

TikTok, Instagram influencers need more rules for drug ads

Continuity nursing helped my family in our darkest PICU moments

Harvard scientists, with Google, unveil the most detailed brain map ever

Drug repurposing or repositioning? The language matters

Readout Newsletter: Biogen, Eisai, Aardvark Therapeutics, etc.

Drug repurposing or repositioning? The language matters

To bolster infectious disease surveillance, genomics powerhouses team up

focus

Printout prescription drug information shouldn’t go digital

Hundreds died while taking an arthritis drug, but nobody alerted patients

Trial using CRISPR to edit HIV out of cells disappoints

A pediatrician calls for Congress to pass the child tax credit deal

HPV vaccine, cervical cancer study delivers historic results

Maisha Meds is a PBM, but don't call it that

hotspot

hotspot

explore

focus